维持性血液透析终末期肾病患者功能性甘露糖结合凝集素水平。
Functional mannose-binding lectin levels in patients with end-stage renal disease on maintenance hemodialysis.
机构信息
Division of Laboratory Medicine, Department of Pathology and Microbiology, Nihon University School of Medicine, Tokyo, Japan.
出版信息
J Innate Immun. 2012;4(3):293-300. doi: 10.1159/000334601. Epub 2012 Feb 1.
BACKGROUND
Innate immunity is generally impaired in chronic renal failure (CRF). Mannose-binding lectin (MBL) has an important role in first-line host defense against pathogens via the lectin pathway. We recently reported that functional MBL was significantly lower in CRF patients than in healthy subjects. In this study, we aimed to determine whether functional MBL would be improved following hemodialysis (HD) therapy.
METHODS
This study included 22 patients with end-stage renal disease (ESRD) on maintenance HD. Functional MBL was measured every 6 months for 1 year after HD using an enzyme-linked immunosorbent assay.
RESULTS
Median serum functional MBL levels of ESRD patients were significantly higher after 6 and 12 months than at the start of HD therapy (p < 0.05 and p < 0.01, respectively). Furthermore, median functional MBL levels at 12 months were significantly higher than those at 6 months (p < 0.05).
CONCLUSIONS
We found significant increases in serum functional MBL levels in patients on HD. Our results indicated that HD tailored to remove uremic toxins could improve functional MBL levels in these patients.
背景
先天性免疫在慢性肾衰竭（CRF）中通常受损。甘露聚糖结合凝集素（MBL）在通过凝集素途径抵抗病原体的第一线宿主防御中具有重要作用。我们最近报道，CRF 患者的功能性 MBL 明显低于健康受试者。在这项研究中，我们旨在确定血液透析（HD）治疗后功能性 MBL 是否会得到改善。
方法
这项研究包括 22 名接受维持性 HD 的终末期肾病（ESRD）患者。使用酶联免疫吸附试验，在 HD 治疗后每 6 个月测量一次功能性 MBL，为期 1 年。
结果
ESRD 患者的血清功能性 MBL 中位数在 HD 治疗开始后 6 个月和 12 个月时明显高于治疗开始时（p < 0.05 和 p < 0.01）。此外，12 个月时的功能性 MBL 中位数明显高于 6 个月时（p < 0.05）。
结论
我们发现 HD 患者的血清功能性 MBL 水平显著升高。我们的结果表明，针对去除尿毒症毒素的 HD 可以改善这些患者的功能性 MBL 水平。
Zotero 插件